Abstract
Rap2, a member of the GTP-binding proteins, is widely upregulated in many types of tumors. The specific effectors of Rap2 can affect multiple cancer-associated cellular processes, including cytoskeleton reorganization, proliferation, migration, and inflammation. However, the functional role of Rap2 in tumorigenesis and the interplay between different effectors remain to be fully elucidated. A more thorough understanding of the cancer-associated signaling networks of Rap2 is expected to facilitate drug discovery targeting Rap2 for cancer therapy. The present review mainly focused on recent studies on the functional and physical interactions between Rap2 and its effectors. We also speculated on the relevance of these pathways to tumorigenesis.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Role of Rap2 and its Downstream Effectors in Tumorigenesis
Volume: 15 Issue: 10
Author(s): Hui Huang, Jiehui Di, Debao Qu, Zhen Gao, Yanping Zhang and Junnian Zheng
Affiliation:
Keywords: Cancer, MAP4K4, PLCε, Rap2, TNIK.
Abstract: Rap2, a member of the GTP-binding proteins, is widely upregulated in many types of tumors. The specific effectors of Rap2 can affect multiple cancer-associated cellular processes, including cytoskeleton reorganization, proliferation, migration, and inflammation. However, the functional role of Rap2 in tumorigenesis and the interplay between different effectors remain to be fully elucidated. A more thorough understanding of the cancer-associated signaling networks of Rap2 is expected to facilitate drug discovery targeting Rap2 for cancer therapy. The present review mainly focused on recent studies on the functional and physical interactions between Rap2 and its effectors. We also speculated on the relevance of these pathways to tumorigenesis.
Export Options
About this article
Cite this article as:
Huang Hui, Di Jiehui, Qu Debao, Gao Zhen, Zhang Yanping and Zheng Junnian, Role of Rap2 and its Downstream Effectors in Tumorigenesis, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (10) . https://dx.doi.org/10.2174/1871520615666150518092840
DOI https://dx.doi.org/10.2174/1871520615666150518092840 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and
Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics
Analysis
MicroRNA Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Potential Role for High and Low Molecular Weight Tissue Transglutaminases in Transforming Mammalian Cell Properties
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer
Current Vascular Pharmacology Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets Assessment of Bishosphonate Activity In Vitro
Current Pharmaceutical Design A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design Role of microRNAs in Hepatic Stellate Cells and Hepatic Fibrosis: An Update
Current Pharmaceutical Design A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry C-20 Cyclopropyl Vitamin D3 Analogs
Current Topics in Medicinal Chemistry Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Apoptosis is a Critical Cellular Event in Cancer Chemoprevention and Chemotherapy by Selenium Compounds
Current Cancer Drug Targets Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry